Core Insights - Kindstar Global and Biostate AI have officially signed an agreement to establish a joint venture aimed at advancing AI-driven precision medical solutions globally, particularly in China [1] - The collaboration will leverage Kindstar Global's extensive clinical testing network covering over 3,000 hospitals in China and Biostate AI's innovative RNA sequencing and AI technology [2][3] - The joint venture will focus on developing innovative diagnostic solutions tailored to the clinical needs in China, enhancing Kindstar Global's leadership in the precision medicine sector [3][4] Company Overview - Kindstar Global is recognized as a leading clinical testing service provider in China, with a robust network that supports the integration of data, diagnostics, and AI [2] - Biostate AI aims to create an AI system that truly understands human biology, enabling personalized medical treatments based on real-time data analysis [2] - The joint venture will initially target five prevalent specialty diseases: autoimmune diseases, oral cancer, diabetes, lymphoma, and post-organ transplant management [4] Strategic Goals - The partnership is seen as a significant milestone in both companies' strategic development, combining Biostate AI's innovative capabilities in RNA sequencing and AI algorithms with Kindstar Global's market expertise [4] - The joint venture will focus on optimizing and validating Biostate AI's RNA sequencing technology for the Chinese population's disease spectrum [4] - The collaboration aims to create a leading global precision medical platform, providing efficient and accurate diagnostic tools for healthcare professionals and patients [4]
康圣环球（09960）与Biostate AI成立合资公司，携手共筑精准医疗新未来